Several meta-analyses of observational studies suggested that metformin use reduces cancer risk in type 2 diabetes, but this result was not confirmed in few available randomized controlled trials. Further, many observational studies on metformin and cancer were potentially afflicted with time-related bias.
Researchers in this study published in Diabetes Care sought to avoid this bias when comparing cancer incidence in users of sulfonylurea, insulin and other diabetes medications, respectively, with cancer incidence in metformin users.
These results offer further evidence on the metformin–reduced cancer risk connection.
READ FULL ARTICLE From Diabetesjournals